<p>Safety and Efficacy of Lenvatinib Treatment in Child–Pugh A and B Patients with Unresectable Hepatocellular Carcinoma in Clinical Practice: A Multicenter Analysis</p>Katsuaki Ogushi, Shin Maeda, Taito Fukushima et al.|Clinical and Experimental Gastroenterology|2020Cited by 55
Early Changes in Circulating FGF19 and Ang-2 Levels as Possible Predictive Biomarkers of Clinical Response to Lenvatinib Therapy in Hepatocellular CarcinomaMakoto Chuma, Shin Maeda, Haruki Uojima et al.|Cancers|2020Cited by 54
Safety and efficacy of atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma in early clinical practice: A multicenter analysisMakoto Chuma, Shin Maeda, Haruki Uojima et al.|Hepatology Research|2021Cited by 50
Analysis of efficacy of lenvatinib treatment in highly advanced hepatocellular carcinoma with tumor thrombus in the main trunk of the portal vein or tumor with more than 50% liver occupation: A multicenter analysisMakoto Chuma, Shin Maeda, Haruki Uojima et al.|Hepatology Research|2020Cited by 38
Clinicopathological Features of Autoimmune Hepatitis with IgG4-Positive Plasma Cell InfiltrationYoshitaka Arase, Tatehiro Kagawa, Koshi Matsumoto et al.|Digestive Diseases|2020Cited by 19